Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with atopic eczema (also called atopic dermatitis) based on a specific set of recognised diagnostic guidelines
- You are starting a new treatment for your eczema, either a light-based therapy (such as UVB light treatment) or a medication that affects the immune system taken by mouth or injection (such as cyclosporin, steroids, azathioprine, methotrexate, mycophenolic acid, or dupilumab)
- You are willing to take part and have signed a consent form, or have a legal guardian who can do this on your behalf
Who may not be able to join:
- You are only taking antibiotics or antihistamines (allergy tablets) to manage your condition, without any of the other treatments mentioned above
- You are starting an immune-suppressing medication for a different health condition, not for eczema
- You or your parent or legal guardian do not have a clear enough understanding of what the study involves to be able to take part fully
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Phyllis I. Spuls, prof.dr., Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands
Phone: +31205662757
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean change in EASI (Eczema Area and Severity Index) score; Mean change in IGA (Investigator's Global Assessment) score; Mean change in POEM (Patient-Oriented Eczema Measure) score; Mean change in PGA (Patient's Global Assessment) score; Mean change in DLQI (Dermatology Life Quality Index) score; Mean time to reach a change in EASI (Eczema Area and Severity Index) score of 50%; The occurrence of severe adverse events; Drug survival of the therapies
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.